Company Overview of Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. The company, through its collaboration agreement with Bayer HealthCare Pharmaceuticals Inc., develops and markets Nexavar tablet, a multiple kinase inhibitor for the treatment of liver cancer and advanced kidney cancer; and Stivarga tablets to treat metastatic colorectal cancer. It is also conducting Phase III clinical trial on Nexavar for the treatment of liver, kidney, thyroid, breast, and non-small cell lung cancers; and completed Phase III clinical trials on Stivarga to treat...
249 East Grand Avenue
South San Francisco, CA 94080
Founded in 1992
Key Executives for Onyx Pharmaceuticals, Inc.
Chief Commercial officer and Executive Vice President
Executive Vice President of Global Research & Development and Technical Operations
Compensation as of Fiscal Year 2013.
Onyx Pharmaceuticals, Inc. Key Developments
U.S. FDA Approves Bayer HealthCare and Onyx Pharmaceuticals' NEXAVAR(R) (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
Nov 22 13
Bayer HealthCare and Onyx Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR(R) (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment. NEXAVAR was approved following a priority review by the FDA, a designation reserved for drugs that may offer a significant improvement in treatment over existing options. The FDA approval is based on the results of the DECISION (stuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine refractory thyrOid caNcer) trial, an international, multicenter, placebo-controlled study. A total of 417 patients with locally recurrent or metastatic, progressive differentiated thyroid carcinoma refractory to radioactive iodine treatment were randomized to receive 400 mg of oral sorafenib twice daily (207 patients) or matching placebo (210 patients). Metastases were present in 96% of the patients: lungs in 86%, lymph nodes in 51%, and bone in 27%. Sorafenib significantly extended progression-free survival (PFS), the primary endpoint of the study. The median PFS was 10.8 months (95% CI 9.1-12.9) among patients treated with sorafenib compared to 5.8 months (95% CI 5.3-7.8) among patients receiving placebo (HR=0.59 [95% CI, 0.46, 0.76]; p<0.001). PFS was evaluated by an independent radiological review committee using modified Response Evaluation Criteria in Solid Tumors (mRECIST). Safety and tolerability were also evaluated. The most common adverse reactions reported for NEXAVAR-treated patients vs. placebo-treated patients in DTC, respectively, were: Palmar-plantar erythrodysesthesia syndrome (PPES) (69% vs. 8%), diarrhea (68% vs. 15%), alopecia (67% vs. 8%), weight loss (49% vs. 14%), fatigue (41% vs. 20%), hypertension (41% vs. 12%), rash (35% vs. 7%), decreased appetite (30% vs. 5%), stomatitis (24% vs. 3%), nausea (21% vs. 12%), pruritus (20% vs. 11%), and abdominal pain (20% vs. 7%). Grade 3/4 adverse reactions were 65% vs. 30%. Drug-related adverse reactions that resulted in treatment discontinuation were reported in 14% of NEXAVAR-treated patients compared to 1.4% of placebo-treated patients.
Onyx Pharmaceuticals, Inc. Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 11:15 AM
Nov 3 13
Onyx Pharmaceuticals, Inc. Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 11:15 AM. Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria. Speakers: N. Anthony Coles, Chairman, Chief Executive Officer and President.
Onyx Pharmaceuticals Inc. Wins Federal Modification Contract for Medical, Dental and Veterinary Equipment
Oct 9 13
VA National Acquisition Center (Department of Veterans Affairs) has awarded Onyx Pharmaceuticals Inc. $6,500,000.00 modified federal contract on October 7, 2013 for medical, dental and veterinary equipment.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 25, 2013
June 30, 2013